405937-75-9

Basic information

• Product Name: 2-bromo-N-(3,5-difluorophenyl)acetamide
• Synonyms: 2-bromo-N-(3,5-difluorophenyl)acetamide
• CAS NO: 405937-75-9
• Molecular Weight: 250.043
• Mol File: 405937-75-9.mol
• Article Data: 11

Chemical Properties

• Boiling Point: 324.3±42.0 °C(Predicted)
• Density: 1.734±0.06 g/cm3(Predicted)
• CAS DataBase Reference: 2-bromo-N-(3,5-difluorophenyl)acetamide(CAS DataBase Reference)
• NIST Chemistry Reference: 2-bromo-N-(3,5-difluorophenyl)acetamide(405937-75-9)
• EPA Substance Registry System: 2-bromo-N-(3,5-difluorophenyl)acetamide(405937-75-9)

Safety Data

• Hazardous Substances Data: 405937-75-9(Hazardous Substances Data)

Upstream product

• 372-39-4 3,5-difluoroaniline 
• 598-21-0 2-Bromoacetyl bromide 

Downstream Products

• 538322-26-8 2-[4-(3'-cyano-biphenyl-4-yl)-1-cyclopentyl-piperidin-4-ylamino]-N-(3,5-difluoro-phenyl)-acetamide 
• 1044504-89-3 N-(3,5-difluorophenyl)-2-[3-(4-formylphenyl)-2-oxo-1,4-diazaspiro[4.5]dec-3-en-1-yl]acetamide 
• 1044504-96-2 1-[N-(3,5-difluorophenyl)glycyl]-3-{4-[(methyloxy)methyl]phenyl}-1,4-diazaspiro[4.4]non-3-en-2-one 
• 1044282-46-3 2-[3-(4-chlorophenyl)-2-oxo-1-azaspiro[4.5]dec-3-en-1-yl]-N-(3,5-difluorophenyl)acetamide 
• 1044500-96-0 N-(3,5-difluorophenyl)-2-{2-oxo-3-[4-(trifluoromethyl)phenyl]-1,3-diazaspiro[4.5]dec-1-yl}acetamide 
• 1132817-41-4 N-(3,5-difluorophenyl)-2-{3-[4-(4-methyl-1H-imidazol-1-yl)phenyl]-2-oxo-1,4-diazaspiro[4.4]non-3-en-1-yl}acetamide formate 
• 1132817-55-0 N-(3,5-difluorophenyl)-2-{2-oxo-3-[4-(2-pyridinyl)phenyl]-7-oxa-1,4-diazaspiro[4.5]dec-3-en-1-yl}acetamide 
• 1196091-40-3 (R)-1-[(3,5-Difluoro-phenylcarbamoyl)-methyl]-3-(1-phenyl-cycloheptanecarbonyloxy)-1-azonia-bicyclo[2.2.2]octane bromide 
• 1338815-89-6 C₂₁H₂₁ClF₂N₂O₂ 
• 1338815-92-1 C₁₉H₁₉ClF₂N₂O₂ 
• 1338815-93-2 C₂₀H₂₁ClF₂N₂O₃S 
• 1338815-94-3 C₂₁H₂₃ClF₂N₂O 
• 1338815-95-4 C₂₁H₂₂ClF₂N₃O₂ 
• 1338815-99-8 C₂₀H₂₆F₂N₂O₃ 

Relevant articles and documents

Searching for New Leads for Tuberculosis: Design, Synthesis, and Biological Evaluation of Novel 2-Quinolin-4-yloxyacetamides

In this study, a new series of more than 60 quinoline derivatives has been synthesized and evaluated against Mycobacterium tuberculosis (H37Rv). Apart from the SAR exploration around the initial hits, the optimization process focused on the improvement of the physicochemical properties, cytotoxicity, and metabolic stability of the series. The best compounds obtained exhibited MIC values in the low micromolar range, excellent intracellular antimycobacterial activity, and an improved physicochemical profile without cytotoxic effects. Further investigation revealed that the amide bond was the source for the poor blood stability observed, while some of the compounds exhibited hERG affinity. Compound 83 which contains a benzoxazole ring instead of the amide group was found to be a good alternative, with good blood stability and no hERG affinity, providing new opportunities for the series. Overall, the obtained results suggest that further optimization of solubility and microsomal stability of the series could provide a strong lead for a new anti-TB drug development program.

Acylglycinamides as inhibitors of glycine transporter type 1

A screening hit was used as the basis for the core structure of a new series of acylglycinamide GlyT-1 inhibitors. Investigation of the SAR around four areas of diversity used facile chemistry to prepare compounds quickly. By focussing on reducing the lipophilicity and improving the aqueous solubility in the series we were able to prepare a compound (17e) with a good level of activity at GlyT-1, selectivity over GlyT-2 and moderate oral bioavailability.

SPIRO-CONDENSED IMIDAZOLONE DERIVATIVES INHIBITING THE GLYCINE TRANSPORTER

Compounds of formula (I) and salts thereof are provided: formula (I), wherein the groups are as defined in the specification. Uses of the compounds as medicaments, and in the manufacture of medicament for treating neurological and neuropsychiatric disorders, in particular psychoses, dementia or attention deficit disorder are also disclosed. The invention further comprises processes to make these compounds and pharmaceutical formulations thereof.